Dexcel Pharma Technologies Ltd.

18 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Jan 2030

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jul 21, 2027
The maintenance fee for Compositions comprising dexamethasone (US 10,537,585) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 12,599,565	Stable Benzimidazole Formulation In force Term ends Jan 31, 2030 · Medium confidence	In force	Term ends Jan 31, 2030	Medium confidence
US 8,865,198	Method for treating a periodontal disease In force Term ends Oct 20, 2031 · From the USPTO record	In force	Term ends Oct 20, 2031	From the USPTO record
US 9,889,090	Method for treating a periodontal disease In force Ends no later than Oct 20, 2031 · From the USPTO record	In force	Ends no later than Oct 20, 2031	From the USPTO record
US 9,757,338	Sustained-release donepezil formulation In force Term ends May 31, 2033 · From the USPTO record	In force	Term ends May 31, 2033	From the USPTO record
US 10,172,882	Pharmaceutical compositions comprising ferric citrate and methods for the production thereof In force Term ends Jun 18, 2035 · From the USPTO record	In force	Term ends Jun 18, 2035	From the USPTO record
US 11,299,583	Alternating and semi-alternating poly(ester-anhydride) copolymers In force Term ends Dec 17, 2035 · From the USPTO record	In force	Term ends Dec 17, 2035	From the USPTO record
US 11,077,055	Orally disintegrating compositions In force Term ends Apr 21, 2036 · From the USPTO record	In force	Term ends Apr 21, 2036	From the USPTO record
US 10,076,494	Stable orally disintegrating pharmaceutical compositions In force Term ends Dec 8, 2036 · From the USPTO record	In force	Term ends Dec 8, 2036	From the USPTO record
US 10,835,488	Stable orally disintegrating pharmaceutical compositions In force Term ends Dec 8, 2036 · From the USPTO record	In force	Term ends Dec 8, 2036	From the USPTO record
US 10,774,176	Alternating and semi-alternating poly(ester-anhydride) copolymers In force Term ends Feb 11, 2037 · From the USPTO record	In force	Term ends Feb 11, 2037	From the USPTO record

10 of 18 patents shown.

Pro members see all 18.

Pro members: see all 18 patents

Also on record, not counted in the 18: 6 lapsed for an unpaid fee · 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned · 16 no status recorded

List them